KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)

Recursion Pharmaceuticals (RXRX) has disclosed Depreciation and Depletion for 5 consecutive years, with $6.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation and Depletion rose 47.62% year-over-year to $6.2 million, compared with a TTM value of $18.3 million through Dec 2024, up 15.09%, and an annual FY2025 reading of $33.7 million, up 84.15% over the prior year.
  • Depreciation and Depletion was $6.2 million for Q4 2024 at Recursion Pharmaceuticals, up from $4.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $6.2 million in Q4 2024 and bottomed at $1.0 million in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $2.9 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Depreciation and Depletion surged 140.0% in 2021, then dropped 4.76% in 2024.
  • Year by year, Depreciation and Depletion stood at $1.1 million in 2020, then skyrocketed by 127.27% to $2.5 million in 2021, then grew by 24.0% to $3.1 million in 2022, then surged by 35.48% to $4.2 million in 2023, then skyrocketed by 47.62% to $6.2 million in 2024.
  • Business Quant data shows Depreciation and Depletion for RXRX at $6.2 million in Q4 2024, $4.0 million in Q3 2024, and $4.1 million in Q2 2024.